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Abstract

Author Manuscript

Many life-cycle processes in parasites are regulated by protein phosphorylation. Hence, disruption
of essential protein kinase function has been explored for therapy of parasitic diseases. However,
the difficulty of inhibiting parasite protein kinases to the exclusion of host orthologues poses a
practical challenge. A possible path around this difficulty is the use of bumped kinase inhibitors
for targeting calcium dependent protein kinases that contain atypically small gatekeeper residues
and are crucial for pathogenic apicomplexan parasites’ survival and proliferation. In this review,
we review efficacy against the kinase target, the parasite growth in vitro, and in animal infection
models, as well as the relevant pharmacokinetic and safety parameters of bumped-kinase
inhibitors.
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Protein kinase inhibitors have been sought for therapy of parasitic diseases, but the challenge
of specific inhibition of parasite kinases versus mammalian kinases has limited their
practical application. Bumped-kinase inhibitors (BKIs) were originally generated in Prof.
Kevan Shokat’s laboratory to build specificity into protein kinase inhibitors that compete
with ATP for the kinase active site (Bishop, et al., 1998, Bishop and Shokat, 1999) The
“bump” on BKIs precludes their binding to almost all mammalian kinases, since these have
a bulky gatekeeper residue in the ATP-binding pocket (see Fig. 1, below). Dr. Shokat’s
group pioneered the use of BKIs in genetically-altered mammalian kinases, in which the
bulky gatekeeper residue was mutated to glycine or alanine, rendering the mutant kinase
susceptible to BKIs (Bishop, et al., 2000, Liu, et al., 1999) If the mutant protein kinase was
active, the mutation could be introduced into the corresponding gene in mice, allowing the
function of that kinase to be probed anytime during the life of the mice by inhibiting that
kinase specifically with BKIs. BKIs had no discernable effects on wild-type mice in control
experiments, providing evidence that these compounds as a class have low activity against
mammalian kinases and hence low toxicity.
We and Dr. Hui’s group determined the structure of Toxoplasma gondii and
Cryptosporidium parvum calcium-dependent protein kinase 1 (CDPK1) and immediately
noticed that these parasite proteins contain a naturally occurring glycine gatekeeper residue
in the ATP binding site (Ojo, et al., 2010, Wernimont, et al., 2010). We reasoned that this
active site should therefore be sensitive to BKI inhibition and found that to be the case
experimentally. Given the safety and specificity of BKIs demonstrated by Shokat’s group,
we embarked on a medicinal chemistry project to optimize BKIs for use against parasites
that have CDPKs, primarily apicomplexans. This review describes progress in this area.

Author Manuscript

2. Structural Basis of Cross-Parasite CDPK inhibition by BKIs
CDPKs have no closely related orthologs in vertebrates, but the CDPK kinase domain is
similar in sequence and structure to other members of the large family of serine threonine
kinases. As with many protein kinases, CDPKs have conformationally distinct active and
inactive states that differ in their competence to bind to and act on their protein substrates.
CDPK activity is not regulated through phosphorylation or interaction with a partner protein.
Instead, regulation is accomplished via a radical reorganization of the calcium-binding
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domain such that in the Ca-bound active state, substrate proteins have unobstructed access to
the face of the CDPK containing the active site, while in the inactive state, access to this face
of the protein is occluded (Ojo, et al., 2010, Wernimont, et al., 2010). The internal
conformation of the active site pocket is unchanged between the active and inactive state.
Even the “inactive” state is catalytically competent to phosphorylate small peptide
substrates, and crystal structures show that the binding pose of ATP, ATP analogs, and ATPcompetitive inhibitors is maintained in both conformations (Murphy, et al., 2010,
Wernimont, et al., 2010). Thus, both the active and inactive states of CDPKs are targeted by
the BKIs discussed here.

Author Manuscript
Author Manuscript

The overall ATP binding pocket comprises three areas necessarily shared by all kinases: a
region adjacent to the ATP β and 7gamma; phosphates containing the catalytic residues, a
relatively hydrophilic pocket that accommodates the ATP ribose moiety, and a relatively
hydrophobic pocket that accommodates the ATP purine group. Given this set of necessarily
shared features, how is it possible to systematically design highly selective ATP-competitive
compounds that potently inhibit target CDPKs in apicomplexan parasites while showing
weak or no inhibition of mammalian kinases? The first key is a difference in the
hydrophobic pocket that accommodates the ATP purine group. In a typical kinase the
accessible volume of this pocket is limited by the side chain of a particular residue, the
“gatekeeper” residue, whose position in the active site is strongly conserved (Zuccotto, et al.,
2010). The surface of the binding site formed by this gatekeeper sidechain is near atom N7
of the ATP purine group and in a typical kinase prevents recognition of ATP analogs that
have been chemically modified by the addition of a bulky group, colloquially called a
“bump”, at this position. Substitution of a small amino acid (i.e., glycine, alanine, or serine)
at the gatekeeper position removes this restriction, resulting in an enlarged hydrophobic
pocket that can accommodate ATP analogs with such a bump. As noted above, BKIs were
originally developed to exploit engineered large to small gatekeeper substitutions to create
highly specific biological probes of kinase function (Bishop, et al., 2001, Bishop, et al.,
2000). Because small gatekeepers are universally rare in wild type mammalian kinases,
pairing the introduction of an engineered sensitive kinase with a suitable bumped ATP
analog or inhibitor constitutes a highly selective probe for that specific kinase (Zhang, et al.,
2005).

Author Manuscript

Various CDPK family members in apicomplexan parasites naturally possess a small
gatekeeper residue. CDPK1 homologs from Toxoplasma gondii, Cryptosporidium parvum,
Neospora caninum, and Sarcocystis neurona contain a glycine gatekeeper. CDPK4 from
Plasmodium falciparum contains a serine. Previously characterized BKIs such as the
pyrazolopyrimidines (PP) (Liu, et al., 1999) presented an obvious starting point for
optimization of inhibitors highly selective for the target parasite enzymes over most host
kinases (Johnson, et al., 2012, Lourido, et al., 2013, Murphy, et al., 2010). Human kinases
containing a threonine gatekeeper, the next smallest amino acid, were thought to account for
the initially imperfect BKI selectivity. Crystallographic comparison of BKIs bound to
CDPK1 and to the representative threonine gatekeeper human kinase SRC showed that it is
possible to increase selectivity by exploiting differences among kinases in the relative
orientation of the ribose binding pocket (Larson, et al., 2012). This led to an optimization
strategy that explored simultaneous substitution at two positions in the starting PP scaffold.
Exp Parasitol. Author manuscript; available in PMC 2018 September 01.
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Substituents at the R1 position, the BKI “bump”, strongly reduce acceptance of gatekeepers
larger than threonine; substituents at the R2 position extend into the ribose pocket and
further restrict acceptance by threonine gatekeeper kinases.

Author Manuscript

The geometric presentation of the R1 and R2 groups characterized for the original PP
scaffold is preserved by analogous substitutions onto an alternative 5-aminopyrazole-4carboxamide (AC) scaffold (Huang, et al., 2015, Zhang, et al., 2014). Thus both scaffolds
exploit the same two primary determinants of CDPK1-specific inhibition (Fig. 1). The
pharmacological properties of compounds based the two scaffolds differ, however. Both
scaffolds are represented in the set of compounds discussed below that have shown the most
promise in animal tests. Two other BKI scaffolds (Fig. 2) that do not preserve this precise
geometry of presenting substituents have also been explored to target apicomplexan CDPKs,
imidazopyridazines to target PfCDPK1 (Chapman, et al., 2013, Chapman, et al., 2014,
Green, et al., 2016), and benzoylbenzimidazoles to target TgCDPK1 and CpCDPK1 (Zhang,
et al., 2012).

Author Manuscript

Joint optimization of the R1 and R2 substituents has led to inhibitors that are >200-fold
more active in vitro against CDPKs than against a panel of 80 to 240 human kinases
(Vidadala, et al., 2016, Zhang, et al., 2014). This selective difference in activity is
sufficiently great to offer hope that further chemical elaboration, in particular of the R2
group, may allow distinguishing selectively between threonine-gatekeeper kinases of
parasite and host. This extends the range of parasitic diseases potentially treatable with BKI
drugs to include those caused by Plasmodium (Chapman, et al., 2013), Eimeria (Keyloun, et
al., 2014), Theileria (Hines, et al., 2015), and Babesia (Pedroni, et al., 2016), all of which
express threonine gatekeeper CDPKs. A validation of CDPK(s) as the sole molecular
target(s) that cause inhibition of growth and proliferation of an apicomplexan parasite cells
when exposed to BKIs will still need chemical genetic determination as demonstrated in T.

gondii.

3. Inhibition of Apicomplexan parasite growth and replication by BKIs
3.1. Toxoplasma

Author Manuscript

Toxoplasma gondii is a protozoan parasite that is broadly distributed throughout the world
infecting mammals and birds, providing a large reservoir for human infection (Tenter, et al.,
2000). Human toxoplasmosis is most often asymptomatic or causes mild, self-limited
symptoms, which includes the formation of tissue cysts that persist in the host brain and
other organs indefinitely. However, severe infections may cause blindness, disability or
death. Persons previously infected with T. gondii (and hence are still carrying parasite cysts)
who have AIDS or who have undergone allogeneic stem cell transplantation are at the
greatest risk of developing toxoplasmosis (Martino, et al., 2005). The primary disease
manifestation in immunocompromised patients is encephalitis, although ocular, pulmonary
and disseminated toxoplasmosis also occur (Rabaud, et al., 1994) . Healthy persons may
develop uveitis, and relapsing uveitis may lead to retinal scarring and loss of vision. The
incidence of ocular disease varies geographically and is noted to be exceptionally high in
areas of Brazil, possibly due to the prevalence of genetically distinct strains that circulate in
South America (Dubey, et al., 2012, Khan, et al., 2006). Toxoplasma encephalitis and
Exp Parasitol. Author manuscript; available in PMC 2018 September 01.
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relapsing ocular disease result from the reactivation of tissue cysts, which are not eliminated
by currently used anti-Toxoplasma medicines. Congenital toxoplasmosis results when an
initial primary infection of a pregnant woman spreads to the fetus, which may cause
miscarriage or developmental defects in the brain and eyes. Other human to human
transmission is restricted to transfusions or transplants, reducing the propensity for the
spread of drug resistance.

Author Manuscript

First line therapy for toxoplasmosis, the combination of pyrimethamine and sulfadiazine, has
a high rate of toxic side effects that can lead to discontinuation of treatment (Dannemann, et
al., 1992, Katlama, et al., 1996, Porter and Sande, 1992). Therapy for Toxoplasma
encephalitis begins with six weeks of treatment that is then continued until immune
reconstitution. The duration of treatment for congenital infection is at least one year while
ocular infection is four to six weeks and may be extended to prevent relapse (Harrell and
Carvounis, 2014, McLeod, et al., 2006). Improved therapy for toxoplasmosis would be
orally available for use in resource-poor settings, achieve high brain and eye concentrations
to treat encephalitis and uveitis and would be active against both the acute replicating
tachyzoite and latent bradyzoite stages within tissue cysts. Moreover, new drugs should also
prioritize having fewer, milder side effects and being effective in pregnancy.

Author Manuscript

Inhibition of T. gondii calcium-dependent protein kinase 1 (TgCDPK1) has proven to be
effective in models of experimental toxoplasmosis. TgCDPK1 regulates the calciumdependent pathway of T. gondii microneme secretion and is required for gliding motility,
host cell invasion and host cell egress (Lourido, et al., 2010). BKIs have been shown to halt
T. gondii proliferation by blocking host-cell invasion and egress (Lourido, et al., 2010,
Murphy, et al., 2010, Ojo, et al., 2010). However, parasites overexpressing CDPK1 with its
glycine gatekeeper replaced by methionine are resistant to multiple BKIs (Johnson, et al.,
2012, Ojo, et al., 2010, Vidadala, et al., 2016). Interestingly, T. gondii mitogen-activated
protein kinase like 1 (TgMAPKL1, which has a serine gatekeeper) has been described as a
secondary target for the BKI 1NM-PP1, based on the finding that a mutation in its
gatekeeper residue was associated with decreased susceptibility to 1NM-PP1 and similar
BKIs (Sugi, et al., 2015). Polypharmacology is common with kinase inhibitors, so it will be
important to evaluate each BKI for its target specificity.

Author Manuscript

BKI synthesis based on the PP scaffold has resulted in potent TgCDPK1 inhibitors (Johnson,
et al., 2012, Larson, et al., 2012, Murphy, et al., 2010, Vidadala, et al., 2016). Lourido et al.
(2013) described a series of PP analogs. In this series, compounds 11 and 24 were
metabolically stable and had in vitro EC50s of 250 nM and 610 nM. These compounds
increased 30 day survival in mice infected with the type II Pru-LUC strain and decreased
brain cysts when administered intraperitoneally prior to infection at 5 mg/kg for 10 days
(Lourido, et al., 2013). Larson et al reported that development of the PP scaffold by adding a
6-alkoxy-2-naphthyl group at the R1 position, and a 4-piperidinylmethylene group at the R2
position further increased selectivity (Doggett, et al., 2014, Larson, et al., 2012). These BKIs
were >15,000 fold more active against TgCDPK1 compared to the human kinases SRC and
ABL (which are among the rare human kinases with threonine gatekeeper residues), with no
inhibition of the human kinases at 20 μM. BKI-1294 (Fig. 3), which was synthesized with
N-methylation of the 4- piperidinyl-methylene substituent to improve metabolic stability,
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had an in vitro EC50 of 140 nM and reduced acute T. gondii infection in mice by 93% when
given orally (or per os, P.O.) at 30 mg/kg (Doggett, et al., 2014). Upon further testing,
BKI-1294 was found to inhibit the human Ether-à-go-go-Related Gene (hERG) ion channel,
preventing further advancement for human toxoplasmosis due to the risk of cardiotoxicity.
Vidadala et al., 2016 investigated modifications of the PP scaffold that maintained efficacy
and selectivity for TgCDPK1 while eliminating hERG liability. Compound 32, also known
as BKI-1553 (Fig. 3), in their series of BKIs had a > 10 μM IC50 against hERG, a 60 nM in
vitro EC50 against T. gondii. BKI-1553 eliminated peritoneal T. gondii infection when
administered P.O. to mice at 20 mg/kg for 5 days. In the latent T. gondii infection model
using the ME49 strain, 30 mg/kg of BKI-1553 reduced the number of brain tissue cysts by
89%. Pharmacokinetic studies in non-infected mice demonstrated a brain to plasma
concentration ratio of 0.33 (Vidadala, et al., 2016), indicating good penetration for treatment
of brain cysts.

Author Manuscript

Development of the 5-aminopyrazole-4-carboxamide (AC) scaffold identified BKIs 1586
and 1643 as lead compounds (Fig. 3). BKI-1643 had an in vitro EC50 of 45 nM against T.
gondii, and in an acute in vivo model using the RH strain, BKI-1643 reduced infection in the
peritoneum below the limits of detection when given P.O. at 20 mg/kg for 5 days (Huang, et
al., 2015). BKIs 1586 and 1643 had a brain to plasma concentration ratio of 0.16 and 0.43,
respectively.

Author Manuscript

In addition to the PP and AC scaffolds, an in vitro screen of a library of compounds against
T. gondii identified biphenylimidazoazines as inhibitors of T. gondii growth (Moine, et al.,
2015). Subsequently, a series of 14 imidazo[1,2-b]pyridazines based on the
biphenylimidazoazines were found to inhibit TgCDPK1 in enzymatic studies at IC50s < 1μM
and 7 compounds were found to inhibit T. gondii at EC50s < 1 μM. Several compounds in
this series were found to have EC50s at or below 100 nM against T. gondii with minimal host
cell toxicity, but they could not be further advanced due to pharmacokinetic issues (Moine,
et al., 2015). At this point in preclinical development, BKIs possess the desirable
characteristics of a new drug for toxoplasmosis: oral bioavailability, brain tissue penetration,
pharmacokinetics that allow for once daily dosing, efficacy against acute and latent stages of
T. gondii and no evidence of host toxicity. Although studies to identify the best BKI are
ongoing, several suitable candidates for advanced drug development have emerged. The
spread of drug resistance resulting from drug exposure is very unlikely given the rarity of
human-to-human transmission of T. gondii, however, the development of resistance in
individuals during treatment should be investigated. Given the promising results that have
come from the extensive preclinical evaluation of the BKI class of compounds, BKIs
demonstrate great potential for expanding and improving therapy for toxoplasmosis.

Author Manuscript

3.2. Neospora

Neospora caninum is phylogenetically closely related to Toxoplasma gondii, but several
biological features distinguish these two species, including elements of their life cycle, host
range, pathogenicity and ultrastructure (Hemphill, et al., 2016). Canids, namely dogs,
wolves, dingoes and coyotes, represent definitive hosts, and N. caninum is capable of
infecting and proliferating within a wide range of intermediates hosts, including cattle,
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sheep, goats, and many more (Dubey and Dubey, 2003). Extensive proliferation can lead to
cellular destruction, tissue damage and immunopathology, and thus disease within these
hosts. Neospora infections in humans have never been demonstrated. The parasite owes its
economic importance primarily to the fact that it causes abortion in cattle, and stillbirth
and/or birth of weak calves, with estimated annual losses of around 1.3 billion US dollars in
the 10 countries where data is available (Reichel, et al., 2013). Natural N. caninum infection
in sheep and concomitant Neospora-induced abortion problems have also been reported
(Gonzalez-Warleta, et al., 2014, Moreno, et al., 2012). In addition, N. caninum infection can
result in birth of clinically healthy, but persistently infected calves, which in turn then
vertically transmit the parasite to the next generation. A number of proposed control options
have been modeled, such as testing and culling of seropositive animals, discontinued
breeding with offspring from seropositive cows, and vaccination of susceptible and infected
animals. However, despite enormous efforts, vaccination against neosporosis has proven to
be difficult, thus more recently chemotherapeutical treatment options are being considered
as a potential alternative to limit the economic impact of neosporosis (Monney and
Hemphill, 2014).

Author Manuscript

In general, chemotherapeutic treatment of Neospora-seropositive animals has not been
regarded as an economically viable option, especially since depending on the compounds
used, milk or meat from drug-treated animals would remain unacceptable for consumption
for some time (Dubey, et al., 2007). Nevertheless, experimental studies have revealed
potentially interesting effects of several compounds in vitro and in laboratory animal models
in vivo (reviewed in Hemphill et al., 2016). Many of these compounds or compound classes
were shown previously to be active against other intracellular protozoan parasites, including
Trypanosoma cruzi, the causative agent of Chagas Disease, and Leishmania species
responsible for cutaneous and visceral leishmaniasis, and some exhibited broad-spectrum
anti-parasitic activity against various protozoans and helminths. However, other approaches
identified compounds that inhibited targets that were conserved almost exclusively within
the group of apicomplexan parasites. BKIs that target CDPK1 represent a classical example
of such a targeted cross-species approach.

Author Manuscript

Molecular, structural and phenotypic evidence demonstrated that NcCDPK1 is a promising
molecular target for neosporosis drug development. Recombinant NcCDPK1 was expressed,
purified and screened against a select group of bumped kinase inhibitors (BKIs) previously
shown to have low IC50s against T. gondii CDPK1 and T. gondii tachyzoites. NcCDPK1 was
inhibited by low concentrations of BKIs, and BKI-1294 was chosen as a lead compound
(Ojo, et al., 2014). The three-dimensional structure of NcCDPK1 in complex with BKI-1294
was studied crystallographically, demonstrating the structural basis for binding and
selectivity. Calcium-dependent conformational changes in solution as characterized by
small-angle X-ray scattering are consistent with previous structures in low calcium-state but
different in the calcium-bound active state than predicted by X-ray crystallography (Ojo, et
al., 2014). This implies that additional structural states of CDPK1 exists beyond the X-ray
crystallographic structures with and without bound calcium.
The compound interferes in Neospora host cell invasion and egress, and prolonged exposure
results in the formation of multinucleated parasites, trapped within host cells (Ojo, et al.,
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2014). BKI-1294 exposure in vitro is not directly parasitocidal: only upon long-term in vitro
treatment of infected host cells (>20 days), was a complete clearance of viable tachyzoites
observed. For different Neospora isolates such Nc-1, Nc-Liv, and Nc-Spain7, but also for T.
gondii strains RH and ME49, clearance of intracellular parasites is also always preceded by
the formation of multinucleated parasites with a deregulated gene expression pattern as
evidenced by the simultaneous expression of bradyzoite and tachyzoite antigens (Fig. 4)
(Winzer, et al., 2015).

Author Manuscript

In vivo treatment with BKI-1294 in a standardized neosporosis mouse model (Arranz-Solís,
et al., 2015) is highly efficacious in non-pregnant mice: Oral dosing of BKI-1294 at 50
mg/kg for 5 days in established murine neosporosis resulted in a 10-fold reduced cerebral
parasite burden compared to untreated controls. In addition, BKI-1294 used at the same
dosage did not show any adverse effects in pregnant mice nor in their offspring. BKI-1294 is
the first compound tested so far that achieved excellent protection against vertical
transmission of N. caninum, with only 5% offspring mortality compared to 100% in the
placebo group, and less than 10% of offspring PCR positive in the CNS, compared to 100%
positive in the placebo group (Winzer, et al., 2015). Thus, these data demonstrate proof-ofconcept for BKIs, and 1294 specifically, for therapy of bovine and canine neosporosis, and
BKI-1294 is a prime candidate for further follow-up studies in larger animals. In addition,
other BKIs are currently evaluated in vitro and in vivo.
3.3. Sarcocystis

Author Manuscript

Sarcocystis neurona is the primary causative agent of equine protozoal myeloencephalitis
(EPM), which is a serious neurologic disease that impacts horses in North and South
America (Dubey, et al., 2015, Howe, et al., 2014). The clinical signs of EPM are variable
and can range from acute to chronic, with the potential for neuropathology in all areas of the
central nervous system (CNS) although the spinal cord is most commonly affected. EPM
horses may exhibit a gradual progression of clinical signs such as mild lameness and
asymmetric muscle atrophy, while acutely-affected horses can progress quickly to severe
ataxia or recumbency. Without adequate treatment, the disease is typically fatal. Notably, S.
neurona has also been found to be a significant cause of morbidity and mortality in assorted
marine mammals, including sea otters, seals, and sea lions (Carlson-Bremer, et al., 2012,
Dubey, et al., 2001, Lapointe, et al., 1998, Lindsay, et al., 2001, Miller, et al., 2010,
Rosonke, et al., 1999).

Author Manuscript

Like its close relatives T. gondii and N. caninum, S. neurona has an obligatory two-host life
cycle that includes the opossums Didelphis virginiana in North America (Fenger, et al.,
1995) and Didelphis albiventris in South American (Dubey, et al., 2001) as the definitive
host. The natural intermediate hosts are various small mammals such as skunks (Cheadle, et
al., 2001), raccoons (Dubey, et al., 2001), and armadillos (Cheadle, et al., 2001). Horses and
marine mammals become infected when they ingest S. neurona sporocysts/oocysts that have
been passed in the feces of infected opossums.
The traditional anti-folate drug combination of pyrimethamine and a sulfonamide has been
used for decades to treat EPM, with daily administration for at least six months considered
the standard therapy. While rarely serious, the anti-folate drugs can have side effects such as
Exp Parasitol. Author manuscript; available in PMC 2018 September 01.
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bone marrow suppression, anorexia, diarrhea, mild anemia, and neutropenia, and
pyrimethamine is a teratogen that should not be given to pregnant mares (Reed, et al., 2016).
More recently, diclazuril and ponazuril have been developed and approved for use as a
treatment for EPM (Dirikolu, et al., 2006, Furr, et al., 2001, Mackay, et al., 2008). These two
drugs have broad anticoccidial activity in a variety of animal species and are
benzeneacetonitrile compounds related to the herbicide atrazine (Hackstein, et al., 1995).
Nitazoxanide (NTZ) is a broad-spectrum antimicrobial drug that was approved and marketed
for treatment of EPM. Although an effective therapy for treatment of S. neurona infection,
the broad-spectrum activity of NTZ was associated with adverse side-effects in horses (e.g.,
colic), so this drug is no longer available for treatment of EPM.
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Interrogation of S. neurona genome and transcriptome information revealed a CDPK1
homologue with the glycine “gatekeeper” residue found in other apicomplexans, thus
implying that BKIs might be effective against S. neurona infection and EPM. Detailed
examination showed that BKIs bind and inhibit recombinant SnCDPK1 in vitro, and S.
neurona in cell culture was inhibited by four different BKIs at EC50 values of 40–120 nM
(Ojo, et al., 2016). Based on the timing of treatment, it appeared that host cell invasion by
the parasite was blocked by the BKIs, consistent with the role of CDPK1 for regulating
parasite motility and host cell entry (Lourido, et al., 2010, Lourido, et al., 2012, Ojo, et al.,
2010). However, higher BKI concentrations resulted in delayed S. neurona endopolygeny
and apparent arrest just prior to formation of daughter merozoites. These results suggested
that BKI treatment at elevated concentrations might inhibit a second target related to S.
neurona development and cytokinesis, similar to what was observed for N. caninum and T.
gondii (Ojo, et al., 2014, Winzer, et al., 2015). In vivo experiments in a murine model of
sarcocystosis showed that treatment for 30 days with BKI-1553 protected S. neuronachallenged mice. In contrast, challenged and non-treated control mice had severe signs of
neurologic disease resulting in death or the need for euthanasia between 39 and 70 days
post-inoculation. Histologic analysis and bioassay of brain tissues demonstrated parasites in
all 10 non-treated control mice but in only 1 of the BKI-1553-treated mice, indicating that
BKI treatment cleared infection in 90% of mice challenged with S. neurona. Importantly,
BKI-1553 is one of several optimized BKIs lacking the potent hERG inhibitory activity that
precluded the use of the initially-developed related BKI-1294 in humans-(Vidadala, et al.,
2016). Along with these improvements to reduce host toxicity, the experimental results
examining BKI activity against S. neurona infection indicate that these compounds are
promising candidates for developing a new therapy for horses afflicted with EPM.
3.4. Cryptosporidium
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Cryptosporidiosis, a zoonotic or anthroponotic disease caused by the apicomplexan parasites
of the genus Cryptosporidium, is a significant contributor to global diarrheal morbidity and
mortality. Cryptosporidiosis is transmitted in the form of highly resistant, sporulated oocysts
that are infectious at the time of passage and spread by the fecal-oral route. Presumptive
diagnoses of Cryptosporidiosis in calves, for instance, could be made based on age, clinical
signs and symptoms. Laboratory diagnosis is mostly based on identifying oocysts in feces.
Infection takes root in the host’s intestinal epithelial cells and causes watery diarrhea that is
typically self-limiting. However, there is a risk for severe disease in immunocompromised
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persons, such as those suffering from AIDS and malnourished children in developing
countries, with infection becoming persistent, recurring, and life-threatening (Fayer, 1997).
Cryptosporidium has recently been identified as the second and third leading cause of
moderate to severe diarrhea in infants aged 0 to 11 months and 12 to 23 months,
respectively, in various regions of Africa and South Asia (Kotloff, et al., 2013). Current
treatments for cryptosporidiosis, including nitazoxanide and paromomycin, have marginal
efficacy of 1.7 days less diarrhea in normal hosts. These drugs are largely ineffective in
immunocompromised patients and are not approved for use in children under 12 months old
(Pantenburg, et al., 2009), the two groups most at risk from this disease, underscoring the
urgent need for novel therapeutics.
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Like TgCDPK1, C. parvum CDPK1 (CpCDPK1) contains a glycine residue at the
gatekeeper position (Murphy, et al., 2010). For this reason and because of the homology of
the solved crystal structures of the ATP binding sites of Tg and CpCDPK1, BKIs
synthesized to target TgCDPK1 have been analyzed for activity against CpCDPK1. BKIs
were evaluated in vitro to determine enzymatic IC50s against CpCDPK1 and cellular EC50s
against C. parvum cultured in HCT-8 cells. Three of the most potent compounds were the PP
compounds BKI-1294 and BKI-1553, and the AC compound BKI-1517 (Fig. 3)
(Castellanos-Gonzalez, et al., 2016, Castellanos-Gonzalez, et al., 2013, Schaefer, et al.,
2016). These compounds were subsequently assessed in vivo for efficacy in various mouse
and calf models.
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SCID-beige mice infected by oral gavage with C. parvum were dosed P.O. with BKI-1294 at
100 mg/kg or vehicle alone for 10 days (4–14 days post-infection). Those treated with
BKI-1294 showed significant reduction in oocyst shedding and eventual clearance, with only
1 of 7 mice shedding oocysts by 33 days post-infection compared to 6 of 7 control mice
shedding at 33 days post infection (Castellanos-Gonzalez, et al., 2013). Hematoxylin-eosin
stained sections of intestine from mice treated with 1294 displayed a lack of damage to the
intestinal epithelium and a lack of excess apoptotic cells, both of which were observed in the
C. parvum infected control mice but absent in uninfected controls (Castellanos-Gonzalez, et
al., 2013). Similarly, mice treated with BKI-1517 at 60 mg/kg and 120 mg/kg P.O. for 5 days
also showed significant reduction in oocyst shedding (Castellanos-Gonzalez, et al., 2016). At
the higher dose, infection was completely cleared out to 28 days post-infection in 5 of 6
mice; at the lower dose infection was reduced, with only 3 of 6 mice shedding oocysts at 28
days (Castellanos-Gonzalez, et al., 2016).
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Lead BKIs were also screened in vivo against C. parvum infection in neonatal ICR mice
(Schaefer, et al., 2000, Schaefer, et al., 2016). Eight day old mice received a dose of 25
mg/kg of BKI concurrently with infection, then dosed again at 3 hours post-infection (HPI)
and every 12 hours thereafter for nine total doses. Histological examination of the jejunum,
ileum, cecum, and colon showed a 56%, 38%, and 36% reduction of infection in mice
treated with BKI-1294, BKI-1517, BKI-1553 respectively, or (Schaefer, et al., 2016).
Paramomycin treatment of neonates showed significantly lower efficacy, with a reduction of
15% (Schaefer, et al., 2016).
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The same three BKIs were next evaluated in a clinical disease model, treating neonatal
calves infected with C. parvum at 36 to 48 hours old (Imboden, et al., 2012, Schaefer, et al.,
2016). BKI-1294 was dosed in two different groups: group A was given 4 doses total at 10
mg/kg, once daily at 48, 96, 144, and 192 hours-post-infection (HPI); and group B was given
10 doses total at 5 mg/kg every 12 hours 48 - 156 HPI. Treatment group A showed
improvement in daily clinical health scores, increased total urine output, and firmer fecal
consistency, in addition to reduced weight loss and fewer oocysts shed daily when compared
to controls (Schaefer, et al., 2016). However, while this treatment did not reduce total fecal
output when compared to controls, drug concentrations in plasma and stool were
subsequently determined by LC-MS analysis to be below therapeutic levels (essentially
zero) by 48 hours after each dose (Schaefer, et al., 2016). This partial success inspired the
repeat trial, dosing BKI-1294 at 12 hour intervals (group B), which showed significant
improvements over control calves in daily clinical health scores, decreased duration of
diarrhea, decreased total fecal output and firmer fecal consistency, decreased weight loss,
and decreased number of oocysts shed (Schaefer, et al., 2016). BKIs 1517 and 1553 were
also dosed a total of 10 times at 12 hour intervals starting at 48 HPI at 10 mg/kg and 5
mg/kg, respectively. Both also showed significant improvements over control calves in all
parameters when dosed every 12 hours, with the single exception that BKI-1553 failed to
reduce total fecal volume (Schaefer, et al., 2016). Neonatal calf studies showed that, overall,
all three BKIs reduced cryptosporidiosis symptoms and infection levels, with BKIs 1294 and
1517 showing slightly better outcomes compared to BKI-1553 (Schaefer, et al., 2016).
3.5. Plasmodium
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Malaria remains a major cause of morbidity, afflicting over two hundred million people
annually (World Health Organization., 2014). Despite years of exposure to intense malaria
transmission; individuals living in endemic areas have no evidence of sterile immunity to P.
falciparum infection (Tran, et al., 2013). Infections are transmitted through bites of infected
female Anopheles mosquitoes. Infection of humans is primarily due to four Plasmodium
species, namely P. falciparum, P. vivax. P. malariae, and P. ovale. A fifth species, P.
knowlesi, emerging in Malaysia, is reported to cause a zoonotic malaria in humans
(Jongwutiwes, et al., 2004). Malaria parasites alternate between different stages in both
mammalian (asexual) and mosquito (sexual) hosts. Currently used drugs for treatment of
clinical symptoms of malaria erythrocytic (asexual) stage do not prevent the sexual forms
(gametocytes) from infecting mosquitoes, even when prevalence and density of gametocytes
appear low (Schneider, et al., 2006). Even treatment with the two drugs with anti-gametocyte
activity, primaquine and artemisinin combination therapy, are imperfect in stopping
Plasmodium transmission to mosquitoes. Primaquine kills mature but not immature
gametocytes, while artemisinin combination therapy kills immature but not mature
gametocytes (Bousema and Drakeley, 2011, Wilairatana, et al., 2010). Atovaquone was
recently shown to as a strong inhibitor of P. berghei ookinete formation (Delves, et al., 2012)
which makes it a good candidate for malaria transmission blocking indication.
The lack of effective transmission-blocking gametocides is a problem for malaria control
because circulating gametocytes that are infectious to mosquitoes persist for weeks after
anti-malarial therapy (Bousema and Drakeley, 2011, Bousema, et al., 2010). Treated
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individuals, often without symptoms, continue to transmit malaria to abundant mosquitos,
since effective control of Anopheles mosquitoes also remains a formidable challenge
(Wellems, et al., 2009). This emphasizes the need for interventions that prevent parasite
transmission.
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Transmission of malaria parasites and effective transition between these different stages of
life in mammalian and mosquito hosts require elaborately coordinated signal transduction
(Ojo, et al., 2012, Vidadala, et al., 2014). Controlled shifts between high and low levels in
intracellular calcium concentrations have been speculated to influence many of these
processes. Intracellular calcium levels in infectious apicomplexan parasites have long been
associated with invasion, gliding motility, and the secretory pathway; elements that are likely
interrelated (Nagamune and Sibley, 2006). We have recently developed an extended
spectrum class of BKIs to disrupt the transmission of malaria parasites from humans to
mosquitos. It has been demonstrated using chemical genetics that the mechanism of action
of these BKIs is through inhibition of Plasmodium calcium dependent protein kinase 4
(CDPK4) (Ojo, et al., 2014, Ojo, et al., 2012). Previous studies have shown that BKIs, when
ingested by mosquitoes during a blood meal containing malaria gametocytes, inhibit CDPK4
activity and this prevents exflagellation of the male gametocytes (Ojo, et al., 2014, Ojo, et
al., 2012). Exflagellation is the visible outcome of the maturation and activation of male
gametocytes into sperm-like, male gamete cells needed for fertilization of the female
gametes. In simple terms, BKIs act as malaria birth control pills that stop the transmission of
malaria by blocking the mating and further parasite development to infectious stages in the
mosquito. Thus, BKIs could fill an important but often overlooked gap in malaria control. To
block transmission, BKIs must be present in the blood constantly while gametocytes are
present and when a mosquito bites. These parameters therefore require that the inhibitor
needs to be non-toxic, long lasting, and effective at doses that permit long-term treatment
exposure in humans. Highly selective transmission blocking BKIs (Ojo, et al., 2014, Ojo, et
al., 2012, Vidadala, et al., 2014) were successfully designed because the serine gatekeeper
residue in Plasmodium CDPK4 is smaller than that of almost all human kinases. Additional
specificity and potency was provided by the unique conformation of the active site and
hydrogen-bonding sites available to small molecule inhibitors, as well as structural features
that can be exploited to gain further selectivity, as discussed in detail above (Ojo, et al.,
2014, Ojo, et al., 2012, Vidadala, et al., 2014). Specific inhibition of CDPK4 does not appear
to inhibit the asexual blood stages of malaria since most of the asexual stage activity was
lost from our BKI series during optimization for CDPK4 kinase activity and specificity (Ojo,
et al., 2014, Ojo, et al., 2012, Vidadala, et al., 2014). This is important in preventing the
evolution of resistance to BKI drugs. Drugs with activity against asexual parasites regularly
contact their targets in the 1011 to 1012 asexual stage parasites in each person, increasing the
chance of encountering (and selecting) a resistant parasite. Because only about 10
gametocytes are taken up by each mosquito, and BKIs only act against gametocytes in the
mosquito, the likelihood of BKIs encountering a resistant parasite is extremely low. Thus
BKIs could be part of a malaria combination therapy that could stop transmission of
parasites that become resistant to the other components that alleviate the malaria illness.
The active sites of Plasmodium spp. CDPK4 enzymes are highly homologous. We have
demonstrated that BKIs block both rodent and human malaria transmission to mosquitoes
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(Ojo, et al., 2012). This data suggests that BKIs and related compounds are likely to be
useful in blocking the transmission of all five species known to cause human malaria; a
significant public health benefit.
3.6. Babesia

Author Manuscript
Author Manuscript

Babesiosis is a zoonotic disease caused by the apicomplexan genus, Babesia. With more
than 100 species currently recognized, these hemoparasitic protozoans inflict asymptomatic,
mild to fatal diseases to a large diversity of animals including humans. The most
economically devastating disease is bovine babesiosis. Two major Babesia species, B. bovis
and B. bigemina, are responsible for this significant agricultural problem with the latter
species causing a milder illness to livestock. Most often exhibited symptoms are the
characteristic high fever, anemia, anorexia, hemoglobinuria with periodic neurological
sequelae such as incoordination, tilting of the head, teeth grinding, involuntary movements
of the legs and excess salivation caused by B. bovis. In severe and often fatal cases, B. bovisinfected animals eventually suffer from cerebral babesiosis. Bovine babesiosis is a disease of
the adult animals as juveniles are immune until they are at least 6-8 months old (Brown, et
al., 2006, Taylor, et al., 1983). It is endemic to most of the world, and the distribution of the
disease is entirely dependent upon the geographical localization of the tick vector,
Rhipicephalus sp. Countries in Asia, South America, Australia, Europe and Africa are all
affected. North America such as the US is almost devoid of bovine babesiosis due to an
effective, well-coordinated tick eradication program that started in the 1940s. However, an
increase in acaricide resistance of the tick vector and global animal movement are
contributing to the re-emergence of bovine babesiosis in the US. In contrast to animal
babesiosis, human babesiosis, caused by B. microti, has not always been on the radar of
disease surveillance in the US. This tick-borne disease is currently a public health issue,
especially in the Northeast corridor of the US. There, B. microti shares its vector host with
Borrelia sp., the causative agent of Lyme disease. Thus, it has been reported that some Lyme
disease patients also suffer from human babesisosis (Diuk-Wasser, et al., 2016, Knapp and
Rice, 2015).
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There has been substantial research effort and financial funding over the years to develop
preventive and chemotherapeutic remedies against babesiosis for the veterinary and medical
world. Currently, live attenuated vaccines are available for combating veterinary babesiosis
and are widely used in endemic countries such as Australia and Argentina (Gohil, et al.,
2013). For non-endemic countries such as the United States where treatment is the preferred
option, imidocarb dipropionate (3.5 mg/kg) intramuscularly administered is effective
although residual drug metabolite renders the treated animal unmarketable (Coldham, et al.,
1995). For human babesiosis, antibiotic combination therapy is available (Homer, et al.,
2000). However, due to side effects and long treatment regimen, improved treatment
therapies are desired (Vannier, et al., 2015).
BKIs have been established to be specifically inhibitory against apicomplexans such as
Plasmodium, Toxoplasma and Cryptosporidium (see above). Out of >600 of these BKIs
available for testing, a subset was chosen to evaluate if they would inhibit Babesia growth
within the mammalian host (Keyloun, et al., 2014). Using the B. bovis model system to
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evaluate the drug effect, 12 BKIs were selected and added to the growth media of the
parasite culture (Pedroni, et al., 2016). As expected, inhibition ranged from non-responsive
to lethal as compared to the control group. Of the BKIs that were inhibitory, their antiproliferative action was observed as early as 24 hours post-treatment. No specific cellular
phenotypic effect was observed, except for BKI-RM-1-152, which 30 μM constant exposure
blocked egress from the infected erythrocytes, as parasites continued to replicate and
accumulate, an observation shared with the Neospora parasites that are exposed to BKI-1294
in vitro. This resulted in the accumulation of merozoite-like parasites crowding within the
host erythrocyte although the overall erythrocyte size remained unchanged (Pedroni, et al.,
2016). BKI-RM-1-152’s effect was specific to the egression process as the removal of the
drug led to successful egress of these merozoite-like parasites and the freed merozoites
invaded more host cells. This result illustrated the static nature of this particular BKI.
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BKIs clearly have a negative effect on Babesia and can be further exploited for the
development of an effective, specific treatment option against babesiosis. Identification of
the specific BKI target(s) in Babesia and subsequent optimization of the binding affinity of
the BKIs to these targets are logical next steps. These small compounds may also assist in
deciphering cellular pathways of Babesia such as egress, invasion and replication, where
these and many other metabolic pathways remain a significant knowledge gap in this
parasite field.
3.7. Theileria
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Theileria equi is a tick-transmitted apicomplexan hemoprotozoan parasite of equids and an
etiologic agent of equine piroplasmosis (EP), a World Organization for Animal Health (OIE)
reportable disease. T. equi occurs worldwide where tick vectors are present, and it is
estimated that only 10% of the world's equids reside in regions free of EP (de Waal, 1992).
Although the continental USA was declared free of EP in 1988 (United States. Animal and
Plant Health Inspection Service., 2008), several well-described outbreaks of T. equi have
occurred recently in U.S. horses (Scoles, et al., 2011, Short, et al., 2012, Ueti, et al., 2012,
United States. Animal and Plant Health Inspection Service., 2008).
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Although prevention of infection and disease would be ideal, complete control of tick
vectors is extremely difficult, and vaccines against T. equi do not exist. Treatment of infected
animals with the goal to clear infection and eliminate the risk of transmission represents a
feasible strategy for disease control in some regions. Imidocarb dipropionate, a dicationic
diamidine of the carbanilide series of antiprotozoal compounds, has been effective against
some of the T. equi strains causing infections in U.S. horses (Ueti, et al., 2012), making it
the current drug of choice. However, variable responses to imidocarb treatment occur in both
natural and experimental T. equi infection (Butler, et al., 2008, Frerichs, et al., 1973, Grause,
et al., 2013, Knowles, 1996, Kumar, et al., 2003, Kumar, et al., 2009, Kuttler, et al., 1987,
Ueti, et al., 2012), and we have recently documented treatment failure associated with in
vitro imidocarb resistance (Hines, et al., 2015). Moreover, acute adverse effects are common
due to the anticholinesterase activity of the drug (Tecles and Cerón, 2001). These include
spasmodic colic and diarrhea (Meyer, et al., 2005). Therefore, pretreatment with
anticholinergic drugs such as atropine sulfate (Meyer, et al., 2005), glycopyrrolate
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(Donnellan, et al., 2013), or N-butylscopolammonium bromide (Ueti, et al., 2012) is
required. Imidocarb injections are painful and local injection site reactions are common
(Meyer, et al., 2005). The LD50 is 16 mg/kg (only four times the therapeutic dose), and
death is associated with dose-dependent nephrotoxicity and hepatotoxicity (Adams, 1981).
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Because of the documented effectiveness of BKIs against other apicomplexans (reviewed
herein), we recently evaluated the in vitro susceptibility of several T. equi isolates to both
imidocarb dipropionate and to BKI-1294 (Hines, et al., 2015). Similar to other
apicomplexans, T. equi CDPK1 has a small glycine gatekeeper residue within the ATPbinding region (Hines, et al., 2015). Despite a difference in imidocarb susceptibility amongst
isolates (EC50: 6.4 - 414 nM), we observed uniform susceptibility to BKI-1294, albeit at a
considerably higher IC50 of approximately 4.0 μM. The relatively high hERG activity of
BKI-1294 (IC50: 0.767 μM) (Ojo, et al., 2014) likely precludes its use in the horse for
treating T. equi, especially given recent work documenting the sequence and functional
homology of the equine hERG ortholog (Pedersen, et al., 2015). Ongoing work includes
screening additional BKI compounds for those with higher activity against T. equi coupled
with lower to absent hERG activity. Given the large number of recently developed BKI
compounds, it is possible that a promising nontoxic alternative to imidocarb dipropionate
will be identified for the treatment of horses infected with T. equi.
3.8. PK and Safety of Lead BKIs
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Single Dose—While the efficacy of our BKIs against CDPK1 and apicomplexan parasites
are similar for the lead drug candidates, these compounds display diverse in vivo efficacy in
each of the animal models. It is possible that the in vivo variability in BKI efficacy may be
related to their absorption, distribution, metabolism, and elimination (ADME) properties.
Indeed the pharmacodynamics for BKIs against T. gondii and C. parvum might be expected
to be completely different, as T. gondii need to be treated by a systemically-distributed
compound with blood-brain-barrier permeability, whereas C. parvum therapy would need to
reach the large bowel, where C. parvum resides on the apical side of intestinal epithelial
cells. In our evaluation pipeline, we initially characterized the pharmacokinetics of BKIs by
administering a 10 mg/kg P.O. dose to BALB/c mice. In addition, a single 25 mg/kg P.O.
dose of BKI was administered to characterize the fecal levels of the compounds.
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The pharmacokinetic data for our three lead BKIs in adult BALB/c mice indicate that BKIs
1517 and 1553 have higher systemic peak plasma concentrations (Cmax) and plasma
exposures (AUC) compared to BKI-1294 (Table 1) (Huang, et al., 2015, Vidadala, et al.,
2016). BKI-1553 is more tightly bound to plasma proteins than the other two BKIs in mouse
plasma. In addition, BKI-1553 has the largest systemic exposure; over four-fold greater than
BKI-1517, largely because BKI-1517 is cleared more rapidly than BKI-1553.At this time it
is unclear whether systemic concentrations drive the in vivo efficacy of BKIs for
cryptosporidiosis (which is restricted to the gut), though the correlation is quite tight for
toxoplasmosis. Therefore, it is important to note that in a mouse single dose model (25
mg/kg P.O.), the fecal concentrations of BKI-1294 are greater than BKIs 1553 and 1517
(Schaefer, et al., 2016).
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The bioavailability of BKIs 1294 and 1553 was evaluated by characterizing the
pharmacokinetics of each BKI after intravenous (I.V.) and P.O. dosing in rats. Following I.V.
administration to rats, BKI-1553 displayed biphasic kinetics and distributed approximately
to total body water with a volume of distribution at steady state (Vss) of 0.9 L/kg. Following
P.O. administration to rats, BKI-1553 showed slow absorption, with the absorption phase
continuing for 12 hours. The plasma concentrations over the 24 hour period after P.O. dosing
exceeded those observed after I.V. dosing suggesting that BKI-1553 had essentially
complete bioavailability in rats and was greatly improved compared to that of BKI-1294
(46%). Additional studies with BKI-1553 demonstrate that BKI-1553 has a bioavailability of
86% in dogs and 65% in monkeys. Why the bioavailability of BKI-1553 is higher in mice
compared to dogs and monkeys is not clear at this time.
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In addition to mice, we have used calves as a pharmacokinetic and efficacy model for BKIs.
The pharmacokinetics of BKIs 1294, 1517, and 1553 were determined after a single P.O.
dose (10 mg/kg) (Schaefer, et al., 2016, Vidadala, et al., 2016). Similar to the results
observed in the mouse model, BKI-1553 had the highest Cmax value and largest AUC (Table
2) (Vidadala, et al., 2016). In addition, the rank order of t1/2 was the same in mice and
calves. However, unlike the mouse model, BKI-1294 has a smaller oral clearance than
BKI-1517 in the calf model, which results in an increased systemic exposure of BKI-1294
compared to BKI-1517 (Schaefer, et al., 2016, Vidadala, et al., 2016). Differences in
bioavailability between the animal models are possible explanation for this disparity.
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Multiple Dosing—Tolerability and linear pharmacokinetics for BKI-1553 were evaluated
after multiple doses in a mouse model. BKI-1553 was administered at 50 mg/kg every other
day for 5 doses to mice, and plasma concentrations remained >10 μM for the entire duration
of the study with maximum concentrations reaching 43 μM (Vidadala, et al., 2016). The
exposure to BKI-1553 following the last 50 mg/kg dose was higher than what would be
predicted from the single dose studies. The longer t1/2 suggests possible saturation of
metabolism at this dose. A final blood collection was performed at the end of the study and
all blood chemistry results were reported by Phoenix Central Laboratory to be within a
normal range for species and age.
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In addition to mice, the pharmacokinetics of BKIs 1294, 1553, and 1517 were characterized
after multiple doses of BKI to calves. Calves were dosed separately P.O. with either 5 mg/kg
(BKIs 1294 or 1553) or 10 mg/kg (BKI-1517) twice a day for five days (Schaefer, et al.,
2016). Overall, the steady state concentrations observed in the calves were within twofold of
those predicted from the single dose data. As expected, steady state plasma concentrations
for BKI-1553 were approximately 25-fold higher than BKIs 1294 and 1517(Schaefer, et al.,
2016). The ability to accurately predict the steady state concentrations of each BKI indicates
that there is no saturation of metabolism with these dosing conditions. Furthermore, even
during infection steady state concentrations for BKIs 1517 and 1553 could be accurately
predicted using the single dose data from healthy calves. This suggests that the disease
pathology does not have a significant impact on systemic concentrations of BKI, although
further studies are warranted.
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Toxicity—BKIs 1294, 1553, and 1517 were initially screened for cytotoxicity against two
mammalian cell lines HepG2 (liver) and CRL-8155 (lymphoblast). None of these three BKIs
display any signs of toxicity at concentrations of up to 30 μM. In vivo toxicity for BKI-1294
was initially screened by dosing at 40 mg/kg three times a day, and the mice appeared
healthy. In addition, BKI-1294 was not toxic when dosed P.O. at 100 mg/kg daily for 5 days.
Potential toxicity of BKI-1553 was examined in mice by testing two doses (30 mg/kg and
100 mg/kg P.O.) daily for 5 days while observing mice for signs of toxicity and collecting
blood samples. Both groups of mice remained active, well-groomed and appeared healthy
throughout the study. Upon necropsy, there were no gross abnormalities, but histology
revealed mild focal inflammation in the spleen in two of three mice in the 30 mg/kg group.
The only abnormality observed in the 100 mg/kg group was inflammatory infiltrate in the
hepatic lobules in one of three mice. BKI-1517 was dosed at 100 mg/kg once a day for 5
days. Over days 2–5 the mice became less groomed and demonstrated less activity. When
the dose was reduced to 53 mg/kg on day 1 and then 26.5 mg/kg once a day for four days,
the mice remained well-groomed and healthy on each day.
We completed a maximally tolerated dose study to determine the lowest observable adverse
effect level (LOAEL) and the no observable adverse effect level (NOAEL) of BKI-1553.
Mice were dosed with single P.O. doses ranging from 200 mg/kg to 1000 mg/kg. The
LOAEL was observed at 500 mg/kg, and the NOAEL was observed at 400 mg/kg. Mice had
slightly ruffled fur and were less active than the control mice at 3 h following the 500 mg/kg
dose. The lowered activity persisted at 24 hours, but was resolved by 30 hours. In addition,
toxicity in calves was not observed for BKIs 1294 1517, or 1553, but the doses used were
much lower (Schaefer, et al., 2016).
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4. Conclusion
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This review has focused on the utility of BKIs for therapy and prevention of apicomplexan
infections. It is clear that the BKIs will have great utility against those organisms with the
smallest gatekeepers in their CDPK1s, such as T. gondii, N. caninum, S. neurona, and
Cryptosporidium spp (Table 3). Nonetheless, the optimal pharmacodynamics of treatment
for Cryptosporidium spp., which are found in the greatest number in the proximal large
bowel and reside on the tips of epithelial cells and project into the lumen of the gut, are
expected to be quite different compared to T. gondii, N. caninum, and S. neurona, which
cause systemic infection. Gut exposure is probably of primary importance for
Cryptosporidium therapy, but broad systemic distribution is necessary for treatment of T.
gondii, N. caninum, and S. neurona infections The apicomplexan organisms whose essential
CDPKs have larger gatekeeper residues, such as threonine, are more difficult to inhibit
selectively, yet the relatively poor choices of current therapeutics encourage us to continue
development of BKIs for these pathogens. The encouraging results and long lasting plasma
levels of BKIs give us optimism that BKIs can be developed to stop transmission of malaria.
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Highlights
•

Many apicomplexan calcium dependent protein kinases (CDPKs) are
validated drug targets

•

These CDPKs have atypically small gatekeeper residues and are inhibited by
bumped kinase inhibitors (BKIs)

•

Highly selective ATP-competitive BKIs inhibit growth of many apicomplexan
parasites at concentrations non-toxic to mammalian cells and some have
demonstrated proof-of- concept therapy in animal infection models

•

BKIs have potential as therapeutics for diseases caused by apicomplexan
pathogens
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Fig. 1. BKIs core scaffold and orientation with enzymes ATP binding sites

(a) Pyrazolopyrimidines (PP) and alternative 5-aminopyrazole-4-carboxamide (AC) scaffold
chemical backbone for CDPK inhibitors. (b) Typical protein kinase active site. The volume
accessible for ATP binding, indicated by the thick blue line, is limited by the presence of a
large gatekeeper residue, in this case phenylalanine 103 of human CDK9. (c) Active site of
T. gondii CDPK1 with AC scaffold BKI-1517. The large R1 substituent occupies a
hydrophobic region made accessible by the absence of sidechain atoms in the glycine
gatekeeper residue. (d) Active site of N. caninum CDPK1 with PP scaffold BKI-1294. In
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addition to the large R1 group, this inhibitor contains a large R2 group that extends deeper
into the ribose pocket. The three crystal structures shown are 3BLQ, 4ONA, and 4MX9.
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Fig. 2. Imidazopyridazines and benzoylbenzimidazoles

are two other chemical scaffolds previously used as backbone for development of BKIs to
target apicomplexan parasite enzymes.
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Fig. 3. Chemical structures

Chemical structures of lead bumped kinase inhibitors with demonstrated activities against
apicomplexan calcium-dependent protein kinase enzymes and parasites growth and
proliferation.
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Fig. 4. BKI-1294 induces the formation of multinucleated parasite complexes in N.caninum
infected cells

Author Manuscript

A: TEM showing a parasitophorous vacuole containing numerous N. caninum tachyzoites
cultured in the absence of BKI-1294. B. N. caninum tachyzoites were allowed to invade the
host cells and were then treated with BKI-1294 (2.5μM) for 6 days. Note the formation of
multinucleated parasites, still enclosed within a vacuole. n = parasite nucleus; hn = host cell
nucleus. Bars = 1 μm
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